CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Incannex Healthcare Inc. (IXHL) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Incannex Healthcare Inc. (IXHL)

Pharmaceutical Preparations · market cap $42M · as of 2026-07-17

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-04-15 (est.)
Phase 2
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Incannex Healthcare Inc. (IXHL) is a micro-cap pharmaceutical company with 12 employees and a market cap of ~$38M, carrying a single clinical-stage asset: IHL-42X Low Dose in Phase 3 for Obstructive Sleep Apnea. The company holds $74.5M in cash against zero revenue, with a key Phase 3 readout estimated around December 2026.
The catalyst path
  • 2027-04-15 (est.)Phase 2 · IHL-42X: dronabinol + acetazolamideimp 7/10
Pipeline
AssetPhaseIndication
IHL-42X Low DosePhase 3Obstructive Sleep Apnea
IHL-42X: dronabinol + acetazolamidePhase 2Obstructive Sleep Apnea (OSA)
IHL-42X (Optimal Dose)Phase 3Obstructive Sleep Apnea
IHL-42X High DosePhase 3Obstructive Sleep Apnea
Price & technical context
3-month
-40.7%
6-month
-50.3%
12-month
-82.4%
52-wk range
$1.97–$14.37
vs 50-day MA
-32.6%
vs 200-day MA
-48.1%
Realized vol
117.1%
Max drawdown
-96.9%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for IXHL (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.